IL-1ra as a Therapeutic Modality in Sepsis
It has become increasingly evident that our current therapeutic options in the treatment of sepsis are limited and result in an unacceptable high mortality rate. The outcome in severe sepsis and septic shock has not changed appreciably despite improvements in critical care medicine and the introduction of a number of potent, broad-spectrum antimicrobial agents over the past two decades. Septic shock has become a leading cause of mortality in critical care units and current trends would indicate that sepsis will become increasingly common in the future. Clearly, innovative treatment strategies are needed to support the septic patient and improve the outlook in this potentially devastating clinical Syndrome .
KeywordsPlacebo Permeability Toxicity Europe Serine
Unable to display preview. Download preview PDF.
- 6.Okusawa S, Gelfand JA, Ikejima T, Connolly RJ, Dinarello CA (1988) Interleukin-1 induces a shock-like State in rabbits. Synergism with tumor necrosis factor and the effect of cyclooxyge- nase inhibition. J Clin Invest 81: 1162–1172Google Scholar
- 7.Arend WP, Joslin FG, Thompson RC, Hannum CH (1989) An IL-1 inhibitor from human mo- nocytes. Production and characterization of biologic properties. J Immunol 143: 1851–1858Google Scholar
- 13.Aiura K, Gelfand JA, Wakabayashi G, et al. (1991) Interleukin-1 receptor antagonist blocks hypotension in a rabbit mpdel of gram-positive septic shock. Cytokine 3: 498Google Scholar
- 16.Fisher CJ, Slotman G, Opal S, Pribble J, Catalano M, and the IL-lra Sepsis Study Group (1991) Results of a phase II study of IL-lra in the treatment of sepsis Syndrome. American College of Chest Physicians 57th Annual Meeting San Francisco CaliforniaGoogle Scholar
- 17.Opal SM, Fischer CJ, Slotman GJ, et al., and the IL-lra Sepsis Study Group (1992) Phase II interleukin-1 receptor antagonist sepsis Syndrome trial: Analysis of clinical, cytokine, and microbial features with outcome. 32nd Annual Meeting of the Interscience Conference of Antimicrobial Agents and Chemotherapy, Anaheim California Abst 1570Google Scholar
- 18.Gordon G, Fisher CJ, Opal SM, Pribble J, Catalano M (1992) Cost-effectiveness of interleukin-1 receptor antagonist in sepsis. Clin Res 40 (Abst) 254 AGoogle Scholar